Basic Information Experimental Physicochemical Property Pharmacokinetic/Toxicokinetic Property Maximum Dosage Drug Property Radar Chart

Basic Information

Drug ID DDPD01035 ...
Drug Name Procainamide
Molecular Weight 235.3253
Molecular Formula C13H21N3O
CAS Number 51-06-9
SMILES CCN(CC)CCNC(=O)C1=CC=C(N)C=C1
External Links
DRUGBANK DB01035
PubChem Compound 4913
Drugs.com Drugs.com Drug Page

Experimental Physicochemical Property

Property Name Property Value Unit Raw Value Raw Unit Reference
Log P 0.88 - 0.88 - HANSCH,C ET AL. (1995)
Melting Point 167.0 ℃ 165-169 ℃ DRUGBANK
Water Solubility 5050.0 mg/L 5050 mg/L DRUGBANK
pKa 9.32 - 9.32 - SANGSTER (1994)

Pharmacokinetic/ Toxicokinetic Property

Property Name Property Value Unit Raw Value Raw Unit Annotation Factor Reference
Absorption 85.0 % 75-95 % DRUGBANK
Bioavailability 83.0 % 83±16 % PO, oral; The Pharmacological Basis of Therapeutics
C Max 2200.0 ng/ml 2.2 mcg/ml PO, oral; Male, men; adults; The Pharmacological Basis of Therapeutics
C Max 2900.0 ng/ml 2.9 mcg/ml PO, oral;  Female, women; adults; The Pharmacological Basis of Therapeutics
T Max 3.6 h 3.6 h PO, oral; Male, men; adults; The Pharmacological Basis of Therapeutics
T Max 3.8 h 3.8 h PO, oral;  Female, women; adults; The Pharmacological Basis of Therapeutics
Clearance 0.60 L/h/kg 10 ml/min/kg intravenous injection, IV; human, homo sapiens; Human Intravenous Pharmacokinetic Dataset
Volume of Distribution 2.0 L/kg 2.0 L/kg DRUGBANK
Volume of Distribution 1.9 L/kg 1.9±0.3 L/kg Children → ;Obesity ↓ ;RD, renal impairment, Renal disease，including uremia → ;ventricular tachycardia → ;congestive heart disease → ; The Pharmacological Basis of Therapeutics
Volume of Distribution 2.2 L/kg 2.2 L/kg intravenous injection, IV; human, homo sapiens; Human Intravenous Pharmacokinetic Dataset
Half-life 3.5 h ~2.5-4.5 h DRUGBANK
Half-life 3.0 h 3.0±0.6 h Children ↓ ;Neonates ↓ ;RD, renal impairment, Renal disease，including uremia ↑ ;myocardial infarction ↑ ;Obesity → ;ventricular tachycardia → ;congestive heart disease → ; The Pharmacological Basis of Therapeutics
Half-life 3.1 h 3.1 h intravenous injection, IV; human, homo sapiens; Human Intravenous Pharmacokinetic Dataset
Toxicity LD50 95.0 mg/kg 95.0 mg/kg intravenous injection, IV; Rattus, Rat; DRUGBANK
Toxicity LD50 312.0 mg/kg 312.0 mg/kg PO, oral; mouse; DRUGBANK
Toxicity LD50 103.0 mg/kg 103.0 mg/kg intravenous injection, IV; mouse; DRUGBANK
Toxicity LD50 250.0 mg/kg 250.0 mg/kg intravenous injection, IV; rabbit; DRUGBANK
Eliminate Route 45.0 % 30-60 % Urinary excretion; Unchanged drug; DRUGBANK
Eliminate Route 67.0 % 67±8 % Urinary excretion; Unchanged drug; congestive heart disease ↓ ;COPD, Chronic obstructive pulmonary disease ↓ ;CP,cor pulmonale ↓ ;Hepatic cirrhosis, cirr ↓ ; The Pharmacological Basis of Therapeutics
Protein Binding 17.5 % 15-20 % DRUGBANK
Protein Binding 16.0 % 16±5 % The Pharmacological Basis of Therapeutics

Maximum Dosage

Not Available

Drug Property Radar Chart

...

Note: Center: Q1-1.5*IQR, Edge: Q3+1.5*IQR; Q1: Quantile 1, Q3: Quantile 3, IQR: Q3-Q1